Biological
VPM1002 recombinant BCG vaccine clinical trials
Also written VPM1002.
- studies test it
- 11
- open now
- 0
- in phase 3
- 5
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Vakzine Projekt Management GmbH (4) · Serum Institute of India Pvt. Ltd. (3) · Serum Life Science Europe GmbH (1) · Swiss Group for Clinical Cancer Research (1) · University Health Network, Toronto (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses VPM1002 recombinant BCG vaccine is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South AfricaWithdrawnPhase 1/2International Maternal Pediatric Adolescent AIDS Clinical Trials GroupNCT05539989Written as VPM1002 Vaccine
- Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 PandemicCompletedPhase 3Serum Life Science Europe GmbHNCT04387409Written as VPM1002
- Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB RecurrenceCompletedPhase 2/3Serum Institute of India Pvt. Ltd.NCT03152903Written as VPM1002 (Recombinant BCG Vaccine)
- Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in InfantsCompletedPhase 3Serum Institute of India Pvt. Ltd.NCT04351685Written as VPM1002
- VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerCompletedPhase 1/2Swiss Group for Clinical Cancer ResearchNCT02371447Written as VPM1002BC
- Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and SeverityCompletedPhase 3University Health Network, TorontoNCT04439045Written as VPM1002
- Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 PandemicCompletedPhase 3Vakzine Projekt Management GmbHNCT04435379Written as VPM1002
- Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South AfricaCompletedPhase 2Serum Institute of India Pvt. Ltd.NCT02391415Written as VPM1002
- Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South AfricaCompletedPhase 2Vakzine Projekt Management GmbHNCT01479972Written as VPM1002
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South AfricaCompletedPhase 1Vakzine Projekt Management GmbHNCT01113281Written as VPM1002 live vaccine
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male VolunteersCompletedPhase 1Vakzine Projekt Management GmbHNCT00749034Written as VPM1002
Codes
What other systems call VPM1002 recombinant BCG vaccine · ClinicalTrials.gg INT001272
- MeSH (NLM) C000705187VPM1002 recombinant BCG vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705187 | VPM1002 recombinant BCG vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.